Last updated: July 31, 2026

Ponstel, the branded formulation of mefenamic acid, is a mature nonsteroidal anti-inflammatory drug (NSAID) with no meaningful remaining U.S. exclusivity. Its commercial profile is driven by generic pricing, limited differentiation, and steady use in short-term pain and primary dysmenorrhea. Brand-level revenue is not separately disclosed by the historical originators, and the U.S. market is primarily a low-value generic opportunity rather than a branded growth asset.

What is Ponstel and how is mefenamic acid used?

Ponstel contains mefenamic acid, an oral NSAID used for short-term treatment of mild-to-moderate pain and primary dysmenorrhea. The U.S. label limits treatment to seven days for pain and two to three days for dysmenorrhea, reflecting the drug’s intended short-duration use and gastrointestinal, renal, and cardiovascular safety risks (U.S. Food and Drug Administration [FDA], 2019).

Attribute	Ponstel
Active ingredient	Mefenamic acid
Drug class	NSAID
Primary indications	Short-term pain; primary dysmenorrhea
U.S. dosage form	Oral capsules
Typical strength	250 mg
Approval status	Long-established FDA-approved product
U.S. commercial status	Genericized, mature market
Biologic status	Small molecule; no biosimilar pathway
Main competitors	Ibuprofen, naproxen, diclofenac, ketoprofen, other mefenamic acid products

Mefenamic acid inhibits cyclooxygenase-mediated prostaglandin production. Its clinical use is concentrated in episodic treatment rather than chronic disease management. That limits prescription volume per patient and reduces the revenue potential relative to chronic-use therapies.

When did Ponstel lose exclusivity?

Ponstel lost meaningful market exclusivity decades ago. The original U.S. approval dates to the 1960s, placing the product well beyond the term of its original compound and regulatory exclusivities. The product’s commercial position is now determined by generic competition, manufacturing economics, and distribution access.

The relevant exclusivity timeline is:

Milestone	Timing	Commercial effect
Original U.S. approval	1960s	Established the branded product
Original patent and regulatory protection	Expired decades ago	Removed monopoly pricing
Generic entry	Historical, with multiple suppliers	Reduced price and brand demand
Current market	Mature generic market	Low unit economics and limited differentiation

Ponstel does not have the characteristics of a protected specialty product. There is no current U.S. market exclusivity period comparable to new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or a new formulation exclusivity period.

What patents protect Ponstel and mefenamic acid?

No commercially relevant U.S. patent estate protects the original mefenamic acid molecule or the historical Ponstel product. The compound is an old small molecule, and its basic composition-of-matter protection expired long ago.

What is the Orange Book status of Ponstel?

The FDA Orange Book is the principal source for approved drug products, therapeutic equivalence information, and listed patents. Ponstel’s historical approval is associated with mefenamic acid capsules, but the product does not have a meaningful active-patent barrier that would prevent ordinary generic competition in the United States (FDA, 2024a).

The principal IP conclusions are:

No live composition-of-matter protection remains for mefenamic acid.
No current brand-level patent position supports premium pricing.
No biosimilar or biologic patent framework applies.
Any later patents would need to cover a specific formulation, manufacturing process, dosage regimen, or delivery system.
Such patents would not automatically restore broad exclusivity for conventional mefenamic acid capsules.

What formulations are protected by Ponstel patents?

The conventional oral capsule is not commercially differentiated by a significant active formulation patent estate. A company could seek protection for a new dosage form, modified-release system, combination product, or delivery technology, but that would require a separate product-development and patent strategy.

Potential formulation opportunities include:

Formulation strategy	Commercial rationale	Patent strength
Modified-release capsule	Lower dosing frequency	Dependent on technical performance and claim scope
Gastroprotective combination	Reduce NSAID gastrointestinal risk	Requires evidence and combination claims
Lower-dose product	Address tolerability and targeted use	Usually limited differentiation
Oral liquid or dispersible form	Improve administration	May have narrow market size
Topical delivery	Avoid or reduce systemic exposure	Requires substantial formulation validation

A new formulation would face competition from established NSAIDs and would need to demonstrate a clear clinical or adherence advantage. A reformulation alone would not necessarily create a large market.

How strong is the Ponstel patent estate?

The Ponstel patent estate is weak from a market-exclusion standpoint because the core active ingredient and conventional dosage form are old and genericized. Any remaining patents would have narrow relevance unless they cover a commercially important formulation or manufacturing process.

Patent category	Current relevance to Ponstel
Composition of matter	Expired
Original process patents	Expired or commercially ineffective
Conventional capsule formulation	No meaningful broad exclusivity
Method-of-use claims	Potentially narrow and difficult to enforce broadly
New delivery systems	Possible for future products, not the historical brand
Manufacturing patents	May protect process details but rarely block generic supply

Patent strength is therefore low for both litigation leverage and pricing support. The main competitive barriers are regulatory compliance, API supply, quality systems, and customer access rather than patent exclusion.

What is the FDA regulatory status of Ponstel?

Mefenamic acid remains an FDA-approved prescription NSAID. The FDA-approved labeling emphasizes short-term use and contains class warnings associated with NSAIDs, including gastrointestinal bleeding, cardiovascular thrombotic events, renal toxicity, and pregnancy-related risks (FDA, 2019).

The regulatory profile has several commercial effects:

The product has a well-established safety and efficacy record.
Generic manufacturers can rely on the established reference product through the abbreviated new drug application pathway.
Label restrictions limit expansion into chronic pain or long-term inflammatory indications.
Safety warnings constrain direct-to-consumer positioning and reduce the value of premium branding.
The drug competes within a crowded therapeutic class with many inexpensive alternatives.

The product’s regulatory maturity lowers development risk for generic entrants but also limits opportunities for meaningful price premiums.

How many patents cover Ponstel?

No active U.S. patent is needed to explain the current market position of Ponstel. The historical drug is effectively an unprotected, multi-source small-molecule product. Patent-count comparisons are less useful than evaluating whether any patent is both active and commercially blocking.

For conventional mefenamic acid capsules, the relevant conclusion is that the product has no broad, enforceable patent barrier comparable to the estates supporting newer branded medicines. Any patent associated with a specific supplier would likely concern a narrow process or formulation rather than the active ingredient itself.

Which companies are challenging Ponstel?

Ponstel is not subject to a current high-profile Paragraph IV challenge comparable to a newly genericized blockbuster. Generic mefenamic acid products have been available for many years, and competition is based on ordinary ANDA entry, manufacturing scale, price, and supply reliability.

What is the Paragraph IV risk for Ponstel?

Paragraph IV litigation risk is low because the principal patents associated with the original product have expired. A Paragraph IV certification is most relevant when an ANDA applicant challenges a listed patent before expiration. Ponstel’s mature status means generic manufacturers generally do not need to overcome a significant remaining patent estate.

Potential future litigation could arise if a company launches a new formulation or if a supplier asserts a process patent. That would be a product-specific dispute rather than a challenge to the basic mefenamic acid market.

What patent litigation affects Ponstel?

There is no material current U.S. patent litigation affecting the conventional Ponstel or mefenamic acid capsule market. Historical product-related disputes would have limited impact on present commercial conditions because the market has already transitioned to generic supply.

The litigation environment is characterized by:

Low probability of originator patent enforcement.
Limited value in pursuing broad infringement claims against conventional generic capsules.
Greater potential for disputes involving manufacturing processes, API sourcing, trademarks, or product quality.
Minimal settlement leverage because the underlying market is low priced and multi-source.

Are there settlement agreements for Ponstel generic entry?

No commercially significant current settlement agreement controls generic entry for conventional mefenamic acid capsules. The market is too mature for a typical branded-generic settlement to determine launch timing.

Any historical settlement involving a particular supplier would not ordinarily create a broad market barrier unless it included enforceable restrictions that remained active. The absence of a meaningful exclusivity timetable means generic access is governed mainly by FDA approval and manufacturing readiness.

What is the competitive landscape for mefenamic acid?

Mefenamic acid competes in a highly substitutable NSAID market. Its strongest competitors are not necessarily other mefenamic acid manufacturers. They include low-cost ibuprofen and naproxen products, which are widely available and familiar to prescribers and patients.

Competitive product	Main advantage over mefenamic acid	Main limitation
Ibuprofen	Broad availability, low price, extensive consumer familiarity	Short duration; NSAID safety risks
Naproxen	Longer duration and low generic cost	Similar gastrointestinal and cardiovascular risks
Diclofenac	Strong anti-inflammatory use and multiple dosage forms	Higher safety concerns in some populations
Ketoprofen	Established NSAID alternative	Limited differentiation
Mefenamic acid	Established use in dysmenorrhea and short-term pain	Narrow indication profile and limited brand equity

Mefenamic acid retains a clinical niche in dysmenorrhea and episodic pain, but it lacks a strong commercial moat. Physicians can substitute other NSAIDs based on tolerability, patient history, price, and local availability.

What is the financial trajectory of Ponstel?

Ponstel’s financial trajectory is consistent with a mature branded drug that has transitioned to generic competition:

Initial branded growth followed regulatory approval and physician adoption.
Revenue erosion followed patent expiry and generic entry.
Brand demand declined as formularies and prescribers shifted toward lower-cost alternatives.
Current economics are concentrated in generic volume, contract supply, and portfolio efficiency.
Long-term growth is likely to track prescription demand and supply share rather than innovation or price expansion.

No standalone public revenue series for Ponstel is generally reported by the historical brand owners. The product has not been a separately disclosed major revenue driver in public company filings. Financial analysis should therefore avoid treating total mefenamic acid market sales as Ponstel brand revenue.

What is the revenue exposure for manufacturers?

For a generic manufacturer, mefenamic acid is likely to be a small portfolio product unless the company has a strong position in a particular national market. The product can provide incremental revenue from an established manufacturing platform, but it is unlikely to materially affect the valuation of a diversified pharmaceutical company.

Revenue factor	Effect on Ponstel economics
Generic competition	Compresses net price
Short treatment duration	Limits annual units per patient
Low switching costs	Increases substitution risk
Established API	Reduces development cost
Limited brand loyalty	Weakens premium pricing
Multi-country availability	Creates volume opportunities outside the U.S.
Supply interruptions	Can temporarily improve pricing or share

The most attractive commercial opportunities may arise in markets where mefenamic acid remains commonly prescribed for menstrual pain and where local manufacturers have reliable distribution. U.S. economics are less attractive because of generic substitution and intense NSAID competition.

What generic launch scenarios exist for Ponstel?

A conventional generic launch faces low patent risk but limited upside. The primary scenarios are:

Base case: stable low-margin supply

Multiple suppliers continue to sell mefenamic acid capsules. Prices remain low, demand stays relatively stable, and manufacturers compete on availability and contracting.

Upside case: temporary supply disruption

A plant shutdown, API shortage, quality warning, or competitor exit could increase short-term prices and market share for remaining suppliers. This would be a supply-driven event, not a patent-driven opportunity.

Downside case: further commoditization

Additional suppliers, wholesaler consolidation, or formulary substitution could reduce net prices and make the product less attractive to smaller manufacturers.

Product-extension case: differentiated delivery system

A modified-release, lower-dose, topical, or combination product could create a separate commercial opportunity. That strategy would require new clinical, formulation, regulatory, and patent investment.

What manufacturing and IP barriers affect mefenamic acid?

Manufacturing barriers are moderate at the quality-system level but low at the molecule level. Mefenamic acid API is established, and the conventional capsule does not require highly specialized technology. The principal barriers are:

FDA-compliant manufacturing and data integrity.
Reliable API qualification.
Control of impurities and dissolution performance.
Stability across the labeled shelf life.
Supply-chain resilience.
ANDA approval and ongoing post-market compliance.
Commercial access to wholesalers, pharmacies, and institutional buyers.

Process patents may protect a supplier’s particular route or purification method, but they generally do not block all production of mefenamic acid. A manufacturer can often use a non-infringing process if it meets regulatory and quality requirements.

How does Ponstel compare with newer pain medicines?

Ponstel has a lower innovation profile and lower pricing power than newer branded analgesics, combination products, or targeted anti-inflammatory therapies. Its advantages are familiarity, established regulatory status, and generic manufacturing feasibility.

Its disadvantages are more significant commercially:

No meaningful exclusivity.
Limited indication breadth.
No durable formulation differentiation.
Strong substitution by other NSAIDs.
Safety warnings shared across the class.
Low patient retention because treatment is episodic.

The product remains commercially viable as a low-cost generic but has limited potential as a standalone branded growth platform.

What geographic markets are most relevant to Ponstel?

Mefenamic acid is marketed in multiple countries under brand and generic names. Its commercial importance varies by local prescribing patterns, OTC availability of competing NSAIDs, reimbursement rules, and domestic manufacturing capacity.

The product may retain stronger demand in countries where it is a familiar treatment for dysmenorrhea and where physicians routinely prescribe it instead of ibuprofen or naproxen. In the United States, the opportunity is primarily generic and volume-based. In emerging markets, brand recognition and local distribution can support higher relative value, although regulatory and pricing controls remain important.

Key Takeaways

Ponstel is the historical brand for mefenamic acid, an established oral NSAID.
The product has no meaningful remaining U.S. composition-of-matter or brand-level exclusivity.
Conventional mefenamic acid capsules face low patent risk and broad generic competition.
No material current Paragraph IV campaign, settlement structure, or patent litigation controls generic entry.
Brand-level revenue is not separately disclosed and is unlikely to be material for major pharmaceutical companies.
Generic economics depend on price, supply reliability, API access, and distribution.
The main commercial risk is substitution by ibuprofen, naproxen, diclofenac, and other inexpensive NSAIDs.
A future commercial opportunity would require a differentiated formulation, combination product, or delivery system.
Mefenamic acid has no biosimilar risk because it is a small-molecule drug.
The product is best viewed as a mature, low-margin generic asset rather than a protected branded franchise.

Frequently Asked Questions

Does Ponstel still have market exclusivity?

No. Ponstel’s original exclusivity expired decades ago, and conventional mefenamic acid products compete in a generic market.

Is mefenamic acid still FDA approved?

Yes. Mefenamic acid remains an FDA-approved prescription NSAID for short-term pain and primary dysmenorrhea, subject to labeled duration and safety restrictions.

Can a generic company launch mefenamic acid without a Paragraph IV lawsuit?

Yes. Because the original product’s relevant patent protection has expired, a conventional generic launch does not depend on defeating a current broad patent barrier.

Is Ponstel a biologic or does it face biosimilar competition?

No. Ponstel contains the small molecule mefenamic acid. It is regulated through the generic drug pathway, not the biosimilar pathway.

Could a new mefenamic acid formulation receive patent protection?

Yes. A genuinely novel modified-release system, combination product, delivery technology, or manufacturing process could potentially receive patent protection. The scope would apply to the new technology, not automatically to all mefenamic acid products.

References

U.S. Food and Drug Administration. (2019). Ponstel (mefenamic acid) capsules: Prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016812s032lbl.pdf
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
National Library of Medicine. (2024). Mefenamic acid: Drug information and labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
U.S. Food and Drug Administration. (2024c). Hatch-Waxman amendments and abbreviated new drug applications. FDA. https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/abbreviated-new-drug-application-anda-process-simplified-approval-process-generics

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Patent Applications:	4,505
Drug Prices:	Drug price information for PONSTEL
DailyMed Link:	PONSTEL at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avion Pharms	PONSTEL	mefenamic acid	CAPSULE;ORAL	015034-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

PONSTEL Drug Patent Profile

When do Ponstel patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ponstel

AI Deep Research

Questions you can ask:

Summary for PONSTEL

US Patents and Regulatory Information for PONSTEL

PONSTEL Market Dynamics, Patent Status, Generic Competition, and Financial Trajectory